ArticleJournal of translational medicine2026
AMPAR dysregulation in microglia drives vascular pathology in diabetic retinopathy via the P2X7R/NLRP3/IL-1β pathway.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic retinopathy (DR) is a leading cause of visual impairment in working-age adults globally, characterized by chronic retinal inflammation and inner blood-retinal barrier (iBRB) disruption. Glutamate excitotoxicity and microglial activation are key pathogenic contributors, but the molecular links from these events to vascular damage remain unclear—particularly the role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), whose subunit composition (GluR1–4) regulates calcium permeability.
methodsHuman vitreous humor and retinal tissues, streptozotocin-induced DR mice, high glucose (HG)-stimulated BV2 cells, mouse primary retinal microglia, and bEnd.3 endothelial cells were used. Glutamate levels, AMPAR subunit expression, microglial activation, calcium homeostasis, iBRB integrity and the potential mechanism were assessed via biochemical assays, immunofluorescence, transcriptomics, calcium imaging, Evans blue assays, western blot, and ELISA. Interventions included the AMPAR antagonists (perampanel and NASPM), and an IL-1β neutralizing antibody.
resultsElevated glutamate levels were observed in the vitreous of DR patients, diabetic mouse retinas, and HG-treated BV2 cells. Critically, a consistent AMPAR subunit composition change (increased GluR1, decreased GluR2) was confirmed in human diabetic retinas, diabetic mouse retinas, HG-treated BV2 cells, and critically, in primary retinal microglia. This subunit change promoted the formation of calcium-permeable AMPARs, triggering downstream events including calcium overload, activation of the ATP/P2X7R/NLRP3 inflammasome pathway, and subsequent upregulation of IL-1β production. The direct link between AMPAR subunit remodeling, elevated intracellular calcium, and increased IL-1β was further substantiated in primary retinal microglia. Ultimately, this cascade impaired iBRB in vivo and enhanced pro-angiogenic responses in endothelial cells in vitro. Notably, both AMPAR inhibition and IL-1β neutralization effectively reversed these pathological changes.
conclusionsOur findings implicate microglial AMPAR subunit remodeling—favoring Ca²⁺-permeable configuration—as an early trigger of neurovascular inflammation in DR. Targeting the glutamate–AMPAR–P2X7R–IL‑1β cascade may offer a rational strategy to preserve iBRB integrity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.